secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001628280-23-035948
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo reports Q3 net loss $104.2M, cuts 40% of workforce, focuses on neurology
--------------------------------------------------------------------------------

- Net loss $104.2M ($0.59/share) vs $53.2M ($0.34) year ago; revenue $9.4M down from $26.5M.
- Workforce reduction ~40% (~162 roles); Brisbane HQ to close early 2024; headquarters move to Richmond, CA.
- COO Mark McClung and CSO Jason Fontenot leaving Jan 2, 2024; Amy Pooler and Gregory Davis appointed heads of Research and Technology.
- Cash $132.1M at Sep 30, 2023; expects runway into Q3 2024; non-GAAP opex 2024 ~$115-135M (down ~50%).
- Deferring new investments in Fabry and CAR-Treg programs; seeking partners/investors; Fabry Phase 1/2 data update expected early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023035948/0001628280-23-035948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023035948/sgmo-20231101.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-035948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer